Modelling and drug targeting of a myeloid neoplasm with atypical 3q26/MECOM rearrangement using patient-specific iPSCs.
Nakamura M, Chonabayashi K, Narita M, Matsumura Y, Nishikawa M, Ochi Y, Nannya Y, Hishizawa M, Inoue D, Delwel R, Ogawa S, Takaori-Kondo A, Yoshida Y.
Nakamura M, et al.
Br J Haematol. 2024 Oct;205(4):1430-1443. doi: 10.1111/bjh.19720. Epub 2024 Aug 26.
Br J Haematol. 2024.
PMID: 39187468
Our iPSC model reproduced the primary patient's MECOM expression changes and histone H3 lysine 27 acetylation (H3K27ac) patterns in the MECOM promoter and MYC blood enhancer cluster (BENC). Furthermore, we revealed the apoptotic effects of the bromodomain and extra-termina …
Our iPSC model reproduced the primary patient's MECOM expression changes and histone H3 lysine 27 acetylation (H3K27ac) patterns in the MECO …